BROOKS

Brooks Laboratories financials

Market cap
₹194 Cr
Sector
Healthcare

What Brooks Laboratories Limited does

Brooks Laboratories manufactures and markets pharmaceutical formulations from its unit at Baddi, Himachal Pradesh, acting as a CDMO/third-party manufacturer for other pharma companies while also supplying institutional and hospital buyers directly. Its Critical Care Division (CCD), established in 2018, sells critical-care, antibiotic, pain-management/nutritional and ophthalmic products to hospitals through a pan-India team of about 140 medical sales professionals. The company also exports formulations to semi-regulated and non-regulated markets in Africa, Latin America and Asia under manufacturing-facility accreditations from regulators in Yemen, Afghanistan, Cambodia, Ivory Coast and Nigeria, holding over 50 market authorisations across a portfolio of 95+ products.

Segments

  • India – CDMO, Third-Party & Institutional Business
  • Critical Care Division (CCD)
  • International / Export Business
Manufacturing facility
1 unit at Baddi, Himachal Pradesh
Product portfolio
95+ products
Market authorisations
50+
Facility regulatory accreditations
Accredited by regulators in Yemen, Afghanistan, Cambodia, Ivory Coast & Nigeria
Export markets
13+ countries incl. Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan, Nigeria, Lebanon, Mauritius, Sudan, Madagascar, DR Congo, Mozambique, plus other LATAM & Africa regions
Critical Care Division sales team
~140 medical sales professionals, pan-India
Founded 2002Headquarters Baddi, Himachal Pradesh, IndiaEmployees 323 (FY25) Company website

Quarterly results

Q1 FY27: revenue down 10.0%, net profit down 46.4% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue21 21 23 26 23 +13%17 −19%20 −13%23 −10%
EBITDA2 2 2 3 3 +67%1 −54%1 −57%2 −40%
Net profit1 1 1 3 2 +133%0 −68%1 −55%1 −46%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −56.6% 1Y

₹50₹100₹150Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹151.33 on 10 Sept 2025 → ₹65.69. High ₹159.04 (12 Sept 2025), low ₹37.11 (30 Mar 2026).

Financials, as filed

Revenue grew 10.8% a year over 3 years, FY23 to FY26. Operating margin widened to 8.2%.

Year endingFY23FY24FY25FY26
Revenue₹63 Cr₹79 Cr₹83 Cr₹86 Cr
Operating profit₹-26 Cr₹3 Cr₹5 Cr₹7 Cr
Operating margin-42.0%4.1%6.0%8.2%
Interest₹2 Cr₹1 Cr₹1 Cr₹1 Cr
Depreciation₹7 Cr₹2 Cr₹2 Cr₹2 Cr
Net profit₹-27 Cr₹2 Cr₹3 Cr₹6 Cr
Net margin-43.5%1.9%3.7%6.8%
Cash from operations₹1 Cr₹-10 Cr₹3 Cr₹9 Cr
Free cash flow₹0 Cr₹-10 Cr₹2 Cr₹6 Cr
ROCE-11.1%3.5%4.3%5.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹25 Cr₹25 Cr₹25 Cr₹26 Cr₹29 Cr₹29 Cr
Reserves₹40 Cr₹40 Cr₹32 Cr₹43 Cr₹86 Cr₹91 Cr
Borrowings₹8 Cr₹6 Cr₹7 Cr₹6 Cr₹8 Cr₹9 Cr
Other liabilities₹20 Cr₹32 Cr₹29 Cr₹19 Cr₹16 Cr₹17 Cr
Total liabilities₹93 Cr₹103 Cr₹92 Cr₹94 Cr₹140 Cr₹146 Cr
Fixed assets₹15 Cr₹15 Cr₹15 Cr₹14 Cr₹13 Cr₹15 Cr
Capital work in progress₹0 Cr₹1 Cr₹0 Cr₹0 Cr₹1 Cr₹1 Cr
Investments₹47 Cr₹47 Cr₹47 Cr₹47 Cr₹86 Cr₹91 Cr
Other assets₹31 Cr₹40 Cr₹31 Cr₹34 Cr₹40 Cr₹40 Cr
Total assets₹93 Cr₹103 Cr₹92 Cr₹94 Cr₹140 Cr₹146 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

The ownership split has held steady since Jun 2025. The shareholder count grew 8% to 11,161.

Promoters
52.6%
DIIs
10.4%
Public
37.0%

Since Jun 2025

  • Promoters 0.00 pp
  • FIIs 0.00 pp
  • DIIs 0.00 pp

How it drifted, 12 quarters

Over this window promoters fell from 63.6% to 52.6% — −11.0 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 63.6%, DIIs 2.5%, Public 33.9%.Dec '23: Promoters 63.6%, DIIs 3.9%, Public 32.6%.Mar '24: Promoters 63.6%, DIIs 3.9%, Public 32.5%.Jun '24: Promoters 63.6%, DIIs 3.9%, Public 32.5%.Sep '24: Promoters 63.6%, FIIs 0.0%, DIIs 3.9%, Public 32.5%.Dec '24: Promoters 59.1%, FIIs 0.0%, DIIs 3.9%, Public 37.1%.Mar '25: Promoters 52.6%, FIIs 0.1%, DIIs 10.4%, Public 37.0%.Jun '25: Promoters 52.6%, DIIs 10.4%, Public 37.0%.Sep '25: Promoters 52.6%, FIIs 0.0%, DIIs 10.4%, Public 37.0%.Dec '25: Promoters 52.6%, FIIs 0.1%, DIIs 10.4%, Public 36.9%.Mar '26: Promoters 52.6%, FIIs 0.2%, DIIs 10.4%, Public 36.8%.Jun '26: Promoters 52.6%, DIIs 10.4%, Public 37.0%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of Brooks Laboratories Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Atul Ranchal 19.24%unchanged
Rajesh Mahajan 17.36%unchanged
Quant Mutual Fund - Quant Business Cycle Fund Mutual fund9.90%unchanged
Erwin Mahajan 4.10%unchanged
Rajni Ranchal 2.92%unchanged
Savvy Ranchal 2.67%unchanged
Aryan Mahajan 2.47%unchanged
Saras Gupta 2.34%unchanged
Selina Ranchal 1.52%unchanged
Saumik Ketankumar Doshi 1.20%unchanged
One Up Financial Consultants Pvt Ltd 1.02%−0.13 pp
Davinder Kumari 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Brooks Laboratories Limited

Guides on how to read this kind of business and the numbers that matter.